Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Katrin M Sjoquist, Bryan H Burmeister, B Mark Smithers, John R Zalcberg, R John Simes, Andrew Barbour, Val Gebski
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2011
BACKGROUND: In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy. METHODS: To identify additional studies and published abstracts from major scientific meetings, we searched Medline, Embase, and Central (Cochrane clinical trials database) for studies published since January, 2006, and also manually searched for abstracts from major conferences f..View full abstract
Funding Cancer Australia and the NSW Cancer Institute.JRZ is a board member of Australasian Gastro-Intestinal Trials Group (AGITG) who pay for his travel to meetings. JRZ and RJS receive grant funding from Cancer Australia and Cancer Institute (NSW) to the National Health and Medical Research Council Clinical Trials Centre and AGITG as program grants or infrastructure funding. All other authors declare that they have no conflicts of interest.This meta-analysis was funded by grants from Cancer Australia and the NSW Cancer Institute to the National Health and Medical Research Council Clinical Trials Centre and the Australasian Gastro-Intestinal Trials Group. We thank Rhana Pike, who is funded by the Australian National Health and Medical Research Council Clinical Trials Centre, for her valuable assistance with the report; Kathryn Winter for providing results on behalf of the RTOG from their study RTOG 8911; Jurjien Boonstra for providing results from his updated manuscript; Sally Stenning and David Cunningham for providing information on the oesophageal cancer subgroup from the MAGIC trial on behalf of the Medical Research Council; and Stephen Thompson for advice on the concept.